Market Exclusive

Amedisys Inc (NASDAQ:AMED) has coverage initiated with a Equal Weight rating

Analyst Ratings For Amedisys Inc (NASDAQ:AMED)

Today, Barclays initiated coverage on Amedisys Inc (NASDAQ:AMED) with a Equal Weight.

There are 7 Hold Ratings, 6 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Amedisys Inc (NASDAQ:AMED) is Hold with a consensus target price of $109.3333 per share, a potential 15.64% downside.

Some recent analyst ratings include

About Amedisys Inc (NASDAQ:AMED)
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2018, the company owned and operated 421 care centers in 34 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.

Recent Trading Activity for Amedisys Inc (NASDAQ:AMED)
Shares of Amedisys Inc closed the previous trading session at 129,60 −3,17 2,39 % with 128.04 shares trading hands.

Exit mobile version